Arbutus announces positive preliminary phase 1a/1b clinical trial results for ab-729

Arbutus announces positive preliminary phase 1a/1b clinical trial results for ab-729, a proprietary galnac delivered rnai compound in development for people living with chronic hepatitis b.arbutus biopharma corp - positive single dose ab-729 data in chronic hepatitis b subjects supports further clinical development.
ABUS Ratings Summary
ABUS Quant Ranking